Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study

Publisher： Karger

E-ISSN： 2296-5262|37|12|748-755

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.37, Iss.12, 2014-11, pp. : 748-755

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Capecitabine in the Routine Treatment of Advanced Breast Cancer: Results from a Non-Interventional Observational Study in 876 Patients

Oncology Research and Treatment, Vol. 32, Iss. 11, 2009-10 ,pp. : 631-636

Karger

Access to resources Recommend Favorite

Topic: Capecitabine (Xeloda) for metastatic breast cancer

Journal of Clinical Excellence, Vol. 4, Iss. 4, 2002-09 ,pp. : 425-428

Radcliffe Press

Access to resources Recommend Favorite

Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer

Oncology, Vol. 72, Iss. 5-6, 2008-01 ,pp. : 330-337

Karger

Access to resources Recommend Favorite

Phase II Study of an ‘All-Oral’ Regimen of Capecitabine, Idarubicin and Cyclophosphamide for Metastatic Breast Cancer – Safety, Efficacy and Quality of Life

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 520-525

Karger

Access to resources Recommend Favorite

Xeloda^® in the Treatment of Metastatic Breast Cancer

Oncology, Vol. 57, Iss. 1, 1999-07 ,pp. : 16-20

Karger

Access to resources Recommend Favorite